Study guide
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications
Key Takeaways Explain This Topic AI
Febrile seizures occur between 6 months and 5 years (peak at 18 months) with core body temperature ≥38°C in the absence of intracranial infection, systemic metabolic disturbance, or prior afebrile seizures; simple febrile seizures are generalized, last <15 minutes, and do not recur within 24 hours.
Complex febrile seizures exhibit focal features, duration ≥15 minutes, recurrence within 24 hours, or post-ictal Todd paresis; while simple febrile seizures carry a subsequent epilepsy risk of only 1–2% (close to population baseline), complex febrile seizures increase the risk to 5–10%.
Childhood Absence Epilepsy presents between 4 and 10 years with frequent brief (5–15 seconds) staring spells with sudden onset and offset, provoked by hyperventilation and showing 3 Hz generalized spike-and-wave discharges on EEG; ethosuximide is first-line monotherapy, whereas sodium channel blockers (carbamazepine, phenytoin) exacerbate absence seizures.
Infantile Spasms (West syndrome) is a catastrophic epileptic encephalopathy defined by the triad of epileptic spasms in clusters upon awakening, hypsarrhythmia on EEG, and neurodevelopmental regression; first-line therapies are high-dose oral prednisolone or hormonal therapy (ACTH) and vigabatrin (first-line in tuberous sclerosis, requiring age-appropriate ophthalmic assessment for retinal toxicity).
Self-limited epilepsy with centrotemporal spikes (Benign Rolandic Epilepsy) features nocturnal hemifacial motor/sensory seizures, drooling, and speech arrest with centrotemporal sharp waves on sleep EEG, remitting spontaneously in adolescence; Juvenile Myoclonic Epilepsy (JME) requires long-term therapy with levetiracetam or valproate (with strict teratogenicity safeguards in females of childbearing potential).
Last updated: November 2026
Febrile Seizures and Childhood Epilepsy Syndromes
Seizures are among the most frequent neurological emergencies encountered in pediatric practice. A critical competency in pediatric medicine is distinguishing benign, age-limited paroxysmal events—such as simple febrile seizures—from complex febrile seizures, life-threatening CNS infections, and catastrophic epileptic encephalopathies. Accurate syndrome recognition guides appropriate neuroimaging, electroencephalography (EEG), targeted antiseizure medication (ASM) selection, and prognostic counseling.
Febrile Seizures: Epidemiology and Diagnostic Criteria
Febrile seizures are the most common convulsive disorder of early childhood, affecting 2% to 5% of children in Europe and North America, with higher rates (up to 8–10%) reported in Japan. They reflect age-dependent cerebral vulnerability to rapid temperature elevation in an immature, developing brain with heightened neuronal excitability and an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission.
Consensus Diagnostic Criteria (AAP and European Guidelines)
A febrile seizure is formally diagnosed only when all five criteria are met:
Age: Child is between 6 months and 60 months (5 years) of age (peak incidence occurs between 12 and 18 months).
Fever: Elevated core body temperature ≥38.0°C (100.4°F) present before, during, or immediately following the seizure.
Absence of Intracranial Infection: Definite exclusion of meningitis, encephalitis, brain abscess, or other CNS infection.
Absence of Acute Metabolic Derangement: No systemic metabolic disturbance capable of provoking seizures (e.g., hypoglycemia, severe hyponatremia, hypocalcemia).
Absence of Prior Afebrile Seizures: No preceding history of unprovoked (afebrile) epileptic seizures.
Simple vs. Complex Febrile Seizures
Febrile seizures are dichotomized into simple (benign) and complex (atypical) presentations. This distinction dictates the diagnostic workup, risk of recurrence, and likelihood of later unprovoked epilepsy.
Clinical Feature Simple Febrile Seizure (~70–75%) Complex Febrile Seizure (~25–30%) Febrile Status Epilepticus (~5%)
Seizure Duration Brief: <15 minutes (most last <5 min) Prolonged: ≥15 minutes Protracted: ≥30 minutes (continuous or repeated)
Semiologic Pattern Generalized from onset (tonic-clonic, clonic, tonic) Focal onset or focal features (unilateral twitching, eye deviation) Generalized or focal continuous activity
24-Hour Recurrence Single episode in a 24-hour period Recurrent (≥2 episodes within 24 hours or same illness) Continuous or fluctuating without recovery
Post-ictal State Rapid recovery; no persistent neurological deficit Prolonged drowsiness or focal deficit ( Todd paresis ) Deep stupor, coma, or persistent neurological deficit
Routine EEG Not indicated; normal or non-specific slowing Consider on specialist advice if epilepsy is suspected Continuous EEG if seizures persist or recovery is delayed
Neuroimaging (MRI) Not indicated Consider if focal deficits persist or recurrent Consider after stabilization if CNS pathology is suspected
Later Epilepsy Risk 1% to 2% (near baseline population risk of 0.5–1%) 5% to 10% (increases with multiple complex features) Up to 15% to 20%
Recurrence Risk Stratification
Following a first febrile seizure, the overall risk of experiencing a recurrent febrile seizure is approximately 30% to 35% . Four primary risk factors predict recurrence:
Young age at onset (<12–18 months): Strongest single predictor (recurrence risk exceeds 50%).
Lower degree of fever: Seizure occurring at a core temperature <38.5°C.
Shorter duration of fever: Seizure occurring <1 hour after the onset of recognized fever.
Family history: First-degree relative with a history of febrile seizures.
Note
A child with none of these risk factors has a recurrence risk of <15%, whereas a child with all four features has a recurrence risk exceeding 70%.
Risk of Developing Subsequent Afebrile Epilepsy
While simple febrile seizures carry a minimal risk of subsequent epilepsy (1–2%), specific risk factors elevate this hazard:
Pre-existing neurodevelopmental abnormality (e.g., cerebral palsy, global developmental delay, microcephaly).
Complex febrile seizure features (especially focal semiology or febrile status epilepticus).
Family history of afebrile epilepsy in a first-degree relative.
Onset before 12 months of age.
If a child has no risk factors, the risk of epilepsy is ~1%. If one risk factor is present, the risk is ~2–3%. With two or more risk factors, the risk rises to 5% to 10% .
- Emergency Management and Parental Guidance [Child having an active seizure]
- |
- [Time seizure; protect airway; lateral position; nothing in mouth]
- |
- [At 5 minutes: give rescue medicine]
- [Buccal midazolam 0.5 mg/kg (max 10 mg) OR rectal diazepam 0.5 mg/kg]
- |
- [If ongoing 5–10 minutes later: repeat benzodiazepine once]
- [Count doses already given; seek emergency help]
- |
- [Persistent seizure after 2 benzodiazepine doses]
- [IV second-line medicine with airway/respiratory support]
- Acute Resuscitation Protocol
Immediate First Aid: Place the child in the lateral recovery position to prevent aspiration. Loosen tight clothing around the neck. Do not restrain the child and never insert fingers or utensils into the mouth .
Timing: Most febrile seizures terminate spontaneously within 2 to 3 minutes. If the seizure duration reaches 5 minutes , active medical intervention is mandatory to prevent progression to status epilepticus.
First-Line Rescue Medication:
Buccal Midazolam: 0.5 mg/kg (maximum single dose 10 mg). Administered between the lower gum and cheek; preferred in Europe due to rapid transmucosal absorption, ease of administration, and superior efficacy compared to rectal diazepam.
Rectal Diazepam: 0.5 mg/kg (maximum single dose 10 mg; 0.5 mg/kg for age <2 yr, 0.3–0.5 mg/kg for older children).
If seizures continue, seek emergency help and repeat the benzodiazepine once after 5–10 minutes , counting any pre-hospital doses. After 2 doses , ongoing seizures require IV second-line treatment: levetiracetam 40–60 mg/kg, phenytoin 20 mg/kg or fosphenytoin 20 mg PE/kg, with cardiorespiratory monitoring and airway support as needed.
Evidence-Based Parental Counseling on Antipyretics
Symptomatic Relief Only: Antipyretics such as paracetamol (acetaminophen) 15 mg/kg every 4–6 hours and ibuprofen 10 mg/kg every 6–8 hours alleviate discomfort, reduce metabolic demand, and treat systemic pain.
Inefficacy for Seizure Prevention: Multiple randomized, placebo-controlled clinical trials have conclusively demonstrated that antipyretics DO NOT prevent the occurrence or recurrence of febrile seizures . Febrile seizures often occur during the initial precipitous rise in temperature before parents recognize the child is febrile. Counsel parents not to administer round-the-clock antipyretics aggressively under the false assumption that it prevents seizures.
Childhood Epilepsy Syndromes: Electroclinical Hallmarks
The International League Against Epilepsy (ILAE) classifies pediatric epilepsies into distinct electroclinical syndromes based on age of onset, seizure semiology, and pathognomonic EEG patterns. +---------------------------------------------------------------------------------------------------------+
- | MAJOR CHILDHOOD EPILEPSY SYNDROMES |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Syndrome & Typical Onset | Clinical Semiology & EEG Hallmark | First-Line Therapy & Alerts |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Childhood Absence Epilepsy (CAE) | Staring spells (5-15 s), eye blink| Ethosuximide (first-line) |
- | Onset: 4 to 10 years | 3 Hz generalized spike-and-wave | CONTRAINDICATED: Carbamazepine |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Infantile Spasms (West Syndrome) | Clusters of sudden flexion spasms | High-dose Prednisolone or ACTH |
- | Onset: 3 to 12 months | Hypsarrhythmia on interictal EEG | Vigabatrin (first-line in TSC) |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Self-Limited Centrotemporal Spikes | Nocturnal hemifacial twitching | Often no medication needed; |
- | (Benign Rolandic / SeLECTS) | Centrotemporal broad sharp waves | Levetiracetam or Sulthiame |
- | Onset: 3 to 12 years | Activated by non-REM sleep | Spontaneous adolescent remission |
- +------------------------------------+-----------------------------------+--------------------------------+
- | Juvenile Myoclonic Epilepsy (JME) | Morning myoclonic arm jerks | Levetiracetam or Valproate |
- | Onset: 12 to 18 years | 4 to 6 Hz polyspike-and-wave | VALPROATE TERATOGENIC WARNING |
- +------------------------------------+-----------------------------------+--------------------------------+
- 1. Childhood Absence Epilepsy (CAE)
Epidemiology and Clinical Picture: Onset between 4 and 10 years (peak 5–7 years), with a female predominance (60–70%). Manifests as frequent, brief (5 to 15 seconds) episodes of profound behavioral arrest, blank staring, and unresponsiveness , occurring dozens to hundreds of times daily. May be accompanied by subtle automatisms (eyelid fluttering, mouth twitching, lip smacking). Episodes have an abrupt onset and abrupt termination with immediate recovery of full consciousness, without post-ictal confusion or fatigue.
Clinic Provocation: Readily provoked in the examination room by having the child perform hyperventilation for 3 minutes (e.g., blowing on a pinwheel or piece of paper).
EEG Hallmark: Symmetrical, synchronous, bilateral 3 Hz (2.5 to 3.5 Hz) generalized spike-and-wave discharges that arise abruptly from a normal background.
Pharmacotherapy:
First-Line: Ethosuximide (T-type voltage-gated calcium channel blocker in thalamocortical relay neurons). Demonstrates equal efficacy to valproate in terminating absence seizures and normalizing EEG, but with significantly fewer attentional, cognitive, and metabolic adverse effects.
Second-Line: Sodium Valproate or Lamotrigine .
Warning
Contraindicated Medications: Sodium channel blockers ( Carbamazepine, Oxcarbazepine, Phenytoin ) and GABAergic inhibitors ( Vigabatrin, Tiagabine ) aggravate absence seizures and can precipitate absence status epilepticus .
2. Infantile Spasms (West Syndrome)
Epidemiology: Severe epileptic encephalopathy presenting between 3 and 12 months of age (peak 4–7 months), affecting approximately 1 in 2,500 infants.
The Diagnostic Triad:
Epileptic Spasms: Sudden, brief (0.5 to 2 seconds) muscle contractions involving the neck, trunk, and limbs. They present as flexor spasms ("jack-knife" forward bending), extensor spasms (head and trunk extension with arm abduction), or mixed flexor-extensor spasms. Crucially, spasms occur in clusters of 20 to 100+ individual spasms , typically upon waking from sleep or during drowsiness.
Hypsarrhythmia on EEG: Interictal EEG shows a high-voltage, chaotic, disorganized background with continuous, multifocal spike and slow-wave discharges, lacking interhemispheric synchrony, punctuated by sudden voltage attenuation (electrodecremental response) during the actual spasm.
Neurodevelopmental Plateau or Regression: Loss of previously acquired developmental milestones (visual tracking, social smiling, head control, rolling).
Etiology: Underlying structural, genetic, or metabolic etiology in 60–70% of cases, including Tuberous Sclerosis Complex (TSC1/TSC2) , perinatal hypoxic-ischemic encephalopathy, focal cortical dysplasia, Trisomy 21, or inborn errors of metabolism.
First-Line Pharmacotherapy:
Hormonal Therapy: High-dose oral Prednisolone (40–60 mg/day) or intramuscular Adrenocorticotropic Hormone (ACTH) is the primary first-line therapy for non-tuberous sclerosis etiologies.
Vigabatrin (irreversible GABA-transaminase inhibitor): The unequivocal first-line therapy of choice in Tuberous Sclerosis Complex , achieving spasm cessation in >80% of patients.
Warning
Vigabatrin Visual Toxicity: Permanent visual-field loss is a serious risk. Arrange baseline and regular specialist ophthalmic assessment using age-appropriate methods. Infants cannot perform reliable perimetry; ERG/OCT testing is individualized rather than mandatory for every infant.
3. Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS / Benign Rolandic Epilepsy)
Epidemiology: The most common focal childhood epilepsy (15% of all pediatric epilepsies). Onset between 3 and 12 years (peak 7–8 years), with normal baseline neurodevelopment and intelligence.
Semiology: Characteristic nocturnal or early-morning focal motor and somatosensory seizures occurring during sleep or upon waking:
Unilateral hemifacial twitching or tonic contraction.
Paresthesia/numbness of the tongue, cheek, or gums.
Inability to speak ( speech arrest ) despite preserved consciousness and comprehension.
Excessive salivation and drooling, accompanied by guttural gurgling sounds.
May evolve into a generalized tonic-clonic seizure during sleep.
EEG Hallmark: Broad, high-amplitude, diphasic sharp waves localized over the centrotemporal (Rolandic) regions , with a normal background. The epileptiform discharges are characteristically activated and markedly accentuated during non-REM sleep .
Prognosis and Management: Excellent prognosis ; seizures remit spontaneously in adolescence (usually by age 15–16) without residual neurological or cognitive deficits. If seizures are infrequent, nocturnal, and non-disruptive, pharmacotherapy is often omitted. If daytime seizures or significant parental anxiety warrant medication, Levetiracetam or Sulthiame is preferred.
4. Juvenile Myoclonic Epilepsy (JME / Janz Syndrome)
Epidemiology: Onset in adolescence between 12 and 18 years . Accounts for 5% to 10% of all epilepsies.
Semiology:
Myoclonic Jerks: Rapid, shock-like, involuntary muscle contractions of the neck, shoulders, and upper limbs (causing patients to drop cups, smartphones, or hairbrushes), occurring characteristically within 1 to 2 hours of waking in the morning .
Generalized Tonic-Clonic Seizures (GTCS): Experienced by >90% of patients, frequently preceded by a cluster of myoclonic jerks.
Absence Seizures: Present in approximately 30% of cases.
Triggers: Sleep deprivation, sudden awakening, psychological stress, alcohol consumption, and photic stimulation (flickering lights/video games).
EEG Hallmark: Generalized 4 to 6 Hz irregular polyspike-and-wave discharges , frequently accentuated by photic stimulation.
Long-Term Management: JME requires lifelong treatment, as seizure relapse occurs in >80% of patients upon medication withdrawal.
Medication Selection:
First-Line: Levetiracetam or Sodium Valproate .
Caution
Valproate Teratogenicity in Females: Sodium Valproate carries a severe risk of major congenital malformations (~10%, including neural tube defects and cardiac anomalies) and neurodevelopmental disorders/autism spectrum conditions (30% to 40%). Under European Medicines Agency (EMA) regulations, valproate is strictly restricted in female adolescents and women of childbearing potential unless no suitable alternative exists and a pregnancy prevention programme is established. Levetiracetam or Lamotrigine is the preferred first-line agent in adolescent girls.
Overview of Pediatric Antiseizure Medications (ASMs)
Antiseizure Medication Primary Mechanism Clinical Spectrum & First-Line Use Key Adverse Effects & Clinical Warnings
Ethosuximide T-type C a 2 + Ca^{2+} C a 2 + channel blocker First-line monotherapy for Childhood Absence Epilepsy Abdominal pain, nausea, vomiting, headache; ineffective for generalized convulsive seizures
Sodium Valproate GABA enhancement, N a + Na^+ N a + & T-type C a 2 + Ca^{2+} C a 2 + blockade Broad-spectrum (JME, generalized, mixed focal/generalized) Weight gain, alopecia, thrombocytopenia, fatal hepatotoxicity (in under-2s/mitochondrial disorders), teratogenicity
Levetiracetam SV2A synaptic vesicle protein binding Broad-spectrum (focal, generalized, myoclonic, JME) Irritability, behavioral changes, mood lability, aggression; excellent safety profile with minimal drug interactions
Vigabatrin Irreversible GABA-transaminase inhibitor First-line for Infantile Spasms (West syndrome) in Tuberous Sclerosis Permanent visual-field defects (age-appropriate specialist ophthalmic assessment); somnolence
Lamotrigine Voltage-gated N a + Na^+ N a + channel blocker Focal seizures, generalized tonic-clonic, second-line absence Severe cutaneous adverse reactions (Stevens-Johnson syndrome / TEN); requires slow upward dose titration
Carbamazepine Voltage-gated N a + Na^+ N a + channel blocker Focal and focal-to-bilateral tonic-clonic seizures Diplopia, ataxia, hyponatremia (SIADH), leukopenia; aggravates absence and myoclonic seizures